Third Arc Bio Selects First Lead Candidate Under Expanded Adagene Collaboration — Adagene Inc.

Event summary

Third Arc Bio selected its first lead candidate under an amended strategic collaboration with Adagene, utilizing SAFEbody® technology for masked CD3 T cell engagers.
The amended agreement broadens the scope to include Third Arc Bio sponsoring and funding clinical development, increasing potential milestone payments to Adagene.
Adagene retains a no-cost option to develop and commercialize the candidate molecules in Greater China, Singapore, and South Korea.
The original agreement was established in November 2025, focusing on generating masked CD3 T cell engagers against unique tumor-associated antigens.

The big picture

This expanded collaboration underscores the growing strategic importance of Adagene’s SAFEbody® technology in developing next-generation antibody therapies. The shift to an integrated asset and technology partnership highlights the potential for significant financial upside for Adagene, while also positioning Third Arc Bio to leverage Adagene’s platform for innovative cancer immunotherapies. The deal reflects broader industry trends toward collaborative development models in biotech, where specialized technology platforms are increasingly sought after to enhance therapeutic efficacy and safety.

What we're watching

Clinical Development Pace: The pace at which Third Arc Bio advances the lead candidate through clinical trials will determine the timeline for potential milestone payments to Adagene.
Geographic Expansion: Whether Adagene can successfully exercise its option to develop and commercialize the candidate in Greater China, Singapore, and South Korea.
Technology Validation: How the success of this collaboration will validate Adagene’s SAFEbody® technology platform for future partnerships and applications.